Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

Inclusion Criteria: * Males, 50 years or older, who are on an alpha blocker and/or a 5-alpha reductase inhibitor or a combination, and are candidates for interventional therapy. Patients to continue on an alpha blocker and/or 5-alpha reductase inhibitor for at least one-month after the Litx™ treatment, then tapered off medication at physician's discretion. * Patients who understand and have the ability to sign written informed consent prior to any study procedures and discontinuation of exclusionary medications. * Patients with moderate to severe BPH bother score \>3 requiring non-medication intervention. * Patients with an IPSS1 Score of \>15 points. * Maximum urinary flow rate (Qmax) ≤15 mL/sec. * Post void residual volume (PVR) ≤300 mL. * Prostatic volume \>50g by TRUS. Exclusion Criteria: * Patients with any previous minimally invasive or surgical intervention for BPH. * Patients who have enrolled, or are currently enrolled in, another clinical trial for any disease within the past 30 days. * Patients with an active urinary tract infection. * Patients with a urethral stricture. * Patients with a predominant middle lobe obstruction. * Patients who have evidence or history of prostate or bladder cancer. * Patients with a PSA of \>10 ng/ml. If the PSA is 4-10 ng/ml, preliminary biopsy should be done within one-year prior to entry into the study to rule out prostate cancer. * Patients who had a biopsy of the prostate within the past 6 weeks. * Patients with bleeding diathesis. * Patients with clinically significant renal or hepatic impairment. * Patients with neurological conditions felt to affect the bladder or a history of a neurogenic or chronically decompensated bladder. * Patients who daily use a pad or device for incontinence. * Patients who had an episode of unstable angina pectoris, myocardial infarction, transient ischemic attack, or cerebrovascular accident (stroke) within the past 6 months, or peripheral arterial disease with intermittent claudication or Leriches syndrome. * Patient has an interest in future fertility. * Patients with prolonged QT interval at baseline or currently taking medications that prolong QT interval (prolonged QT interval defined as \> 450 ms). * Inadequate organ function as evidenced by the following: Platelet count \<100,000/mm³; WBC \<4,000/mm³; Neutrophils \<1,800/mm³; Hemoglobin \<10 g/dL; SGOT and SGPT \>3 x ULN; Creatinine \>1.2 mg/dL * Known sensitivity to porphyrin-type drugs or known history of porphyria. * Known sensitivity to antibiotics (i.e., levofloxacin, gentamicin, etc.). * Inability to avoid sunlight after procedure during the first 2 weeks after LS11 administration.